Table 1 TCGA AML patient characteristics and TLN1 expression correlated with clinical characteristics
Characteristic | Low expression of TLN1 | High expression of TLN1 | p | Statistic |
|---|---|---|---|---|
N | 75 | 76 | Â | Â |
Gender, n (%) | Â | Â | 0.061 | 3.51 |
 Female | 40 (26.5%) | 28 (18.5%) |  |  |
 Male | 35 (23.2%) | 48 (31.8%) |  |  |
Race, n (%) | Â | Â | 0.887 | Â |
 Asian | 0 (0%) | 1 (0.7%) |  |  |
 Black or African American | 7 (4.7%) | 6 (4%) |  |  |
 White | 66 (44.3%) | 69 (46.3%) |  |  |
Age, n (%) | Â | Â | 0.025* | 5.03 |
  < =60 | 51 (33.8%) | 37 (24.5%) |  |  |
  > 60 | 24 (15.9%) | 39 (25.8%) |  |  |
WBC count(×10^9/L), n (%) |  |  | 0.417 | 0.66 |
  < =20 | 35 (23.3%) | 42 (28%) |  |  |
  > 20 | 39 (26%) | 34 (22.7%) |  |  |
BM blasts(%), n (%) | Â | Â | 0.444 | 0.59 |
  < =20 | 27 (17.9%) | 33 (21.9%) |  |  |
  > 20 | 48 (31.8%) | 43 (28.5%) |  |  |
PB blasts(%), n (%) | Â | Â | 0.932 | 0.01 |
  < =70 | 35 (23.2%) | 37 (24.5%) |  |  |
  > 70 | 40 (26.5%) | 39 (25.8%) |  |  |
Cytogenetic risk, n (%) | Â | Â | 0.077 | 5.12 |
 Favorable | 21 (14.1%) | 10 (6.7%) |  |  |
 Intermediate | 37 (24.8%) | 45 (30.2%) |  |  |
 Poor | 16 (10.7%) | 20 (13.4%) |  |  |
FAB classifications, n (%) | Â | Â | 0.121 | 11.42 |
 M0 | 9 (6%) | 6 (4%) |  |  |
 M1 | 17 (11.3%) | 18 (12%) |  |  |
 M2 | 21 (14%) | 17 (11.3%) |  |  |
 M3 | 11 (7.3%) | 4 (2.7%) |  |  |
 M4 | 12 (8%) | 17 (11.3%) |  |  |
 M5 | 4 (2.7%) | 11 (7.3%) |  |  |
 M6 | 0 (0%) | 2 (1.3%) |  |  |
 M7 | 0 (0%) | 1 (0.7%) |  |  |
Cytogenetics, n (%) | Â | Â | 0.237 | 10.41 |
 Normal | 32 (23.7%) | 37 (27.4%) |  |  |
  + 8 | 4 (3%) | 4 (3%) |  |  |
 del(5) | 1 (0.7%) | 0 (0%) |  |  |
 del(7) | 1 (0.7%) | 5 (3.7%) |  |  |
 inv.(16) | 5 (3.7%) | 3 (2.2%) |  |  |
 t(15;17) | 7 (5.2%) | 4 (3%) |  |  |
 t(8;21) | 6 (4.4%) | 1 (0.7%) |  |  |
 t(9;11) | 0 (0%) | 1 (0.7%) |  |  |
 Complex | 14 (10.4%) | 10 (7.4%) |  |  |
FLT3 mutation, n (%) | Â | Â | 0.846 | 0.04 |
 Negative | 51 (34.7%) | 51 (34.7%) |  |  |
 Positive | 24 (16.3%) | 21 (14.3%) |  |  |
IDH1 R132 mutation, n (%) | Â | Â | 0.235 | 1.41 |
 Negative | 65 (43.6%) | 71 (47.7%) |  |  |
 Positive | 9 (6%) | 4 (2.7%) |  |  |
IDH1 R140 mutation, n (%) | Â | Â | 0.745 | 0.11 |
 Negative | 70 (47%) | 67 (45%) |  |  |
 Positive | 5 (3.4%) | 7 (4.7%) |  |  |
IDH1 R172 mutation, n (%) | Â | Â | 0.245 | Â |
 Negative | 75 (50.3%) | 72 (48.3%) |  |  |
 Positive | 0 (0%) | 2 (1.3%) |  |  |
RAS mutation, n (%) | Â | Â | 0.719 | Â |
 Negative | 70 (46.7%) | 72 (48%) |  |  |
 Positive | 5 (3.3%) | 3 (2%) |  |  |
NPM1 mutation, n (%) | Â | Â | 1.000 | 0 |
 Negative | 58 (38.7%) | 59 (39.3%) |  |  |
 Positive | 17 (11.3%) | 16 (10.7%) |  |  |
OS event, n (%) | Â | Â | 0.112 | 2.52 |
 Alive | 32 (21.2%) | 22 (14.6%) |  |  |
 Dead | 43 (28.5%) | 54 (35.8%) |  |  |